AI model aims to predict recovery after Kidney-Sparing surgery
NCT ID NCT07697417
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study looks at whether combining CT scan images, tumor features, and patient health information can better predict how well people recover after partial nephrectomy for endophytic kidney cancer. Researchers will analyze data from 406 patients who have already had surgery to build and test a computer model. The goal is to improve predictions of complications, kidney function, and cancer recurrence compared to using scans or clinical data alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this model could help doctors better predict recovery and complications after kidney-sparing surgery for hard-to-reach tumors.
- What could go wrong
- This is a retrospective observational study, not a controlled trial. The model may not work as well in other hospitals or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOPHYTIC RENAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Second Hospital
Tianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?
- Robot surgeon takes on kidney and prostate operations
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Lab-Made immune protein takes on advanced cancers in first human test